ACTIVE INGREDIENT: Letrozole
STRENGTH & PACK SIZE & GMS CODES:
2.5 mg Film-Coated Tablets x 30 ~ 24525
Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Extended adjuvant treatment of hormone-dependentearly breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.
Advanced breast cancer in women with natural or artificially induced postmenopausal status after relapse or disease progression, who have previously been treated with anti-oestrogens.
Efficacy has not been demonstrated in patients with hormone receptor negative breast cancer.